331 related articles for article (PubMed ID: 34889355)
21. Administration of Dexrazoxane Improves Cardiac Indices in Children and Young Adults With Acute Myeloid Leukemia (AML) While Maintaining Survival Outcomes.
Schloemer NJ; Brickler M; Hoffmann R; Pan A; Simpson P; McFadden V; Block J; Tower RL; Burke MJ
J Pediatr Hematol Oncol; 2017 Jul; 39(5):e254-e258. PubMed ID: 28452856
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of cardiomyopathy in acute myeloid leukemia patients treated with anthracyclines.
Mort MK; Sen JM; Morris AL; DeGregory KA; McLoughlin EM; Mort JF; Dunn SP; Abuannadi M; Keng MK
J Oncol Pharm Pract; 2020 Apr; 26(3):680-687. PubMed ID: 31500517
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
[TBL] [Abstract][Full Text] [Related]
24. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.
Stěrba M; Popelová O; Vávrová A; Jirkovský E; Kovaříková P; Geršl V; Simůnek T
Antioxid Redox Signal; 2013 Mar; 18(8):899-929. PubMed ID: 22794198
[TBL] [Abstract][Full Text] [Related]
25. Benefits of antihypertensive medications for anthracycline- and trastuzumab-induced cardiotoxicity in patients with breast cancer: Insights from recent clinical trials.
Rygiel K
Indian J Pharmacol; 2016; 48(5):490-497. PubMed ID: 27721532
[TBL] [Abstract][Full Text] [Related]
26. Dexrazoxane as a cardioprotectant in children receiving anthracyclines.
Sepe DM; Ginsberg JP; Balis FM
Oncologist; 2010; 15(11):1220-6. PubMed ID: 21051660
[TBL] [Abstract][Full Text] [Related]
27. Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy.
Cvetković RS; Scott LJ
Drugs; 2005; 65(7):1005-24. PubMed ID: 15892593
[TBL] [Abstract][Full Text] [Related]
28. Minimising the long-term adverse effects of childhood leukaemia therapy.
Langebrake C; Reinhardt D; Ritter J
Drug Saf; 2002; 25(15):1057-77. PubMed ID: 12452732
[TBL] [Abstract][Full Text] [Related]
29. [Dexrazoxane in patients with B-lymphomas or acute leukemias in the 2nd complete remission enables further therapy with cardiotoxic anthracyclines over recommended cumulative doses].
Lemez P; Stejskal J; Cahová S; Holub M; Svítil P; Maresová J; Vásová I; Boudová L; Benesová V; Dvoráková D; Fisar J; Slavícek L
Vnitr Lek; 2004 Jun; 50(6):438-46. PubMed ID: 15346637
[TBL] [Abstract][Full Text] [Related]
30. Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up.
Elbl L; Hrstkova H; Tomaskova I; Michalek J
Support Care Cancer; 2006 Feb; 14(2):128-36. PubMed ID: 16034614
[TBL] [Abstract][Full Text] [Related]
31. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients.
Elbl L; Hrstkova H; Tomaskova I; Blazek B; Michalek J
Eur J Pediatr; 2005 Nov; 164(11):678-84. PubMed ID: 16044276
[TBL] [Abstract][Full Text] [Related]
32. [Economic assessment of dexrazoxane in prophylaxis of cardiotoxicity in children undergoing chemotherapy with anthracyclines].
Fernandes RRA; Vianna CMM; Freitas PG; Guerra RL; Corrêa FM
Cad Saude Publica; 2019 Sep; 35(9):e00191518. PubMed ID: 31531521
[TBL] [Abstract][Full Text] [Related]
33. Aerobic exercise in anthracycline-induced cardiotoxicity: a systematic review of current evidence and future directions.
Chen JJ; Wu PT; Middlekauff HR; Nguyen KL
Am J Physiol Heart Circ Physiol; 2017 Feb; 312(2):H213-H222. PubMed ID: 27923793
[TBL] [Abstract][Full Text] [Related]
34. Cardiotoxicity in anthracycline therapy: Prevention strategies.
Cruz M; Duarte-Rodrigues J; Campelo M
Rev Port Cardiol; 2016 Jun; 35(6):359-71. PubMed ID: 27255173
[TBL] [Abstract][Full Text] [Related]
35. Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
Jirkovský E; Jirkovská A; Bavlovič-Piskáčková H; Skalická V; Pokorná Z; Karabanovich G; Kollárová-Brázdová P; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Lyon AR; Roh J; Šimůnek T; Štěrbová-Kovaříková P; Štěrba M
Circ Heart Fail; 2021 Nov; 14(11):e008209. PubMed ID: 34551586
[TBL] [Abstract][Full Text] [Related]
36. Managing chemotherapy-related cardiotoxicity in survivors of childhood cancers.
Lipshultz SE; Diamond MB; Franco VI; Aggarwal S; Leger K; Santos MV; Sallan SE; Chow EJ
Paediatr Drugs; 2014 Oct; 16(5):373-89. PubMed ID: 25134924
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular disease in adult survivors of childhood cancer.
Lipshultz SE; Franco VI; Miller TL; Colan SD; Sallan SE
Annu Rev Med; 2015; 66():161-76. PubMed ID: 25587648
[TBL] [Abstract][Full Text] [Related]
38. Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma.
Limat S; Daguindau E; Cahn JY; Nerich V; Brion A; Perrin S; Woronoff-Lemsi MC; Deconinck E
J Clin Pharm Ther; 2014 Apr; 39(2):168-74. PubMed ID: 24384030
[TBL] [Abstract][Full Text] [Related]
39. Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II
Kollárová-Brázdová P; Jirkovská A; Karabanovich G; Pokorná Z; Bavlovič Piskáčková H; Jirkovský E; Kubeš J; Lenčová-Popelová O; Mazurová Y; Adamcová M; Skalická V; Štěrbová-Kovaříková P; Roh J; Šimůnek T; Štěrba M
J Pharmacol Exp Ther; 2020 Jun; 373(3):402-415. PubMed ID: 32253261
[TBL] [Abstract][Full Text] [Related]
40. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Henriksen PA
Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
